SecBot SecBot
144 ·Filed May 13, 2026
RC

RCKTW

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001959173-26-003569
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale by an insider following equity vesting. The dollar amount is negligible relative to market cap. No trading action warranted; monitor for any larger insider sales or changes in beneficial ownership.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+20
Entry
$0.0193
T+0 close · May 13, 2026 · via day close
Latest settled
0.00%
T+20 · $0.0193
Vs SPY
+0.61%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 13 $0.0193entry
  2. T+1 · 6mo ago 0.00%α −0.78% · $0.0193
  3. T+5 · 6mo ago 0.00%α +0.14% · $0.0193
  4. T+20 · 5mo ago 0.00%α +0.61% · $0.0193
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent to sell 2,728 shares of common stock, with an approximate market value of $9,836. The shares were acquired on May 11, 2026, through restricted stock vesting as compensation. This is a routine, small-dollar sale by an insider to cover tax obligations from equity vesting, with no material impact on the company's outlook.

Key Facts

  • Insider Gaurav Shah (Officer and Director) filed Form 144 to sell 2,728 shares
  • Estimated sale value: $9,836.08
  • Shares acquired on May 11, 2026 via restricted stock vesting (compensation)
  • Sale is to cover tax obligations from vested equity award distribution
  • Company market cap is approximately $1 million (RCKTW)

Financial Impact

Approximately $9,836, less than 1% of the company's market cap

dilution

Risk Factors

  • Insider selling pattern could emerge if additional Form 144s are filed
  • Low market cap and limited liquidity may amplify any selling pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-003569
Document: 0001959173-26-003569-index.html0001959173-26-003569
Document: 0001959173-26-003569.txt0001959173-26-003569

Track record

4 reports on RCKTW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 13, 202626w ago 144 Neutral 2/10 Viewing Entry $0.0193 No price data
  2. May 7, 202627w ago 8-K Mixed 6/10 Entry $0.0193 to $0.001800 ▼ −90.67% −95.51% vs SPY
  3. May 7, 202627w ago 144 Neutral 3/10 Entry $0.0193 to $0.003200 ▼ −83.42% −87.25% vs SPY
  4. Apr 28, 202628w ago 8-K Bullish 8/10 Entry $0.0193 to $0.002700 ▼ −86.01% −90.00% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026